The purpose of this study is to develop and implement a methodology of digital tools paired with telemedicine to improve cascade testing for clinically significant germline mutations among family members of children with cancer who have a pathogenic or likely pathogenic(P/LP) germline variant in a cancer predisposition gene.

Inclusion Criteria:

• Biological parent of a child enrolled in the ORIGen cohort (AEPI24N1) who has a confirmed P/LP germline variant in a CPG.
• 18 years of age or older.
• Speak and understand English.

Exclusion Criteria:

• Previous genetic testing for the familial variant.

• Communication difficulties such as:

  • Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded.
  • Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.
  • Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks.